BioLife secures CAR T-cell therapy development deal

By The Science Advisory Board staff writers

October 4, 2021 -- BioLife Solutions has secured a deal with an undisclosed global pharmaceutical company to support that firm's regulatory and commercial launch of a new CAR T-cell therapy.

Under the terms of the deal, the pharmaceutical firm will use BioLife's CryoStor media, the evo cold-chain management platform, and SciSafe storage with Stirling UltraCold freezers.

The company's CryoStore freeze media is currently being used by Kite/Gilead, Bluebird Bio, and Bristol Myers Squibb, it said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.